Details:

Corporate Authors:
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination. ; New Jersey Medical School. Global Tuberculosis Institute.
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination. ; New Jersey Medical School. Global Tuberculosis Institute. Less -
Description:
Developed in partnership with the New Jersey Medical School Global Tuberculosis Institute.

This guide is intended for primary care providers who care for individuals and populations who may be at risk for infection with Mycobacterium tuberculosis. Latent tuberculosis infection (LTBI) is the presence of Mycobacterium tuberculosis in the body without signs and symptoms, or radiographic or bacteriologic evidence of tuberculosis (TB) disease.

Approximately one-third of the world’s population is infected with M. tuberculosis. It is estimated that more than 11 million people

in the United States have LTBI, which is about 4% of the total population. While not everyone with LTBI will develop TB disease, about 5 – 10% of infected people will develop TB disease if not treated. This equates to approximately 550,000 to 1,100,000 people who will develop TB at some point in their life, unless they receive adequate treatment for LTBI. Identifying and treating those at highest risk for TB disease will help move toward elimination of the disease. Primary care providers play a key role in achieving the goal of TB elimination because of their access to high-risk populations.

Guidelines for testing and treating LTBI were released by the Centers for Disease Control and Prevention (CDC) and the American Thoracic Society (ATS). They can be found in the June 9, 2000 issue of Morbidity and Mortality Weekly Report (MMWR), entitled Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection.

More recently, recommendations for the use of interferon-gamma release assays (IGRAs) were released in the June 25, 2010 issue of Morbidity and Mortality Weekly Report (MMWR), entitled Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium Tuberculosis Infection. In addition, recommendations for a new regimen for the treatment of LTBI were introduced. They can be found in the December 9, 2011 issue of Morbidity and Mortality Weekly Report (MMWR), entitled Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection.

List of abbreviations -- Introduction -- Targeted testing for tuberculosis -- Diagnosis of latent TB infection (LTBI) -- Treatment of latent TB infection -- Appendix A: Sample TB Risk Assessment Tool -- Appendix B: identifying persons from high-risk countries -- Appendix C: Administration and measurement of the TST -- Appendix D: Certain situations where results from both TST and IGRA may be useful -- Appendix E: Sample TST and treatment documentation forms -- Resources – References.

CDC-INFO Pub ID 220468


Content Notes:
220468
Subjects:
[+]
Interferon-gamma Release Tests Latent Tuberculosis/diagnosis Latent Tuberculosis/drug Therapy Tuberculin Test
Document Type:
Book
Genre:
Guideline
Collection(s):
Stephen B. Thacker CDC Library collection
Main Document Checksum:
[+]
urn:sha256:18e1df2c7557c7e9a77d6bb4686282d546d4903303f0c3f627c8ddc1755eff61
Download URL:
https://stacks.cdc.gov/view/cdc/22030/cdc_22030_DS1.pdf
File Type:

Supporting Files

• No Additional Files

More +